The Muscular Dystrophy Core Center at UCLA is comprised of a group of scientists interested in the development of therapeutics for degenerative muscle disease. The goal of the Center is to improve and facilitate the process of discovery and pre-clinical testing for muscular dystrophy by providing resources, pilot funding and an intellectually rich environment that promotes research progress and encourages productive interactions between muscle researchers and other researchers in related disciplines on campus. The existence of the Center will attract scientists that are both established muscle researchers and those that have not previously conducted muscle research and, with this association, add new expertise and experience to the group. The Cores will use high throughput and non-invasive analyses based on novel cellular assays and novel genetically modified mouse models. The high throughput and non-invasive strategies being used by Center Scientists are not traditionally associated with muscle disease and may thereby foster novel advancements and rapid development of therapeutics. The Center membership reflects a variety of different scientific expertise that will facilitate this endeavor.
The aims of the Administrative Core are to coordinate the activities of the Center and to facilitate these goals. Specifically the Aims of the Administrative Core are:
Aim 1 : To provide administrative support to the Cores and all activities of the Center.
Aim 2 : To facilitate collaboration between Center Scientists and encouragement of Core usage by organizing enrichment activities such as a seminar series, annual retreat and maintenance of a website.
Aim 3 : To oversee review and funding of pilot and feasibility projects.
Aim 4 : To facilitate data sharing and use of the cores from the greater community of dystrophy researchers so that the cores will provide a national resource for muscular dystrophy research.
Muscular dystrophies are a group of devastating neuromuscular disorders with substantial morbidity and premature death. Duchenne MD in particular is the most common, lethal, inherited disorder with an incidence of 1 in 3,000 live male births. Current therapeutic approaches are inadequate and most treatment plans are directed at palliative care. The focus of this Core Center is to use cutting edge, highthroughput assays to identify new therapeutic strategies.
|DiFranco, Marino; Kramerova, Irina; Vergara, Julio L et al. (2016) Attenuated Ca(2+) release in a mouse model of limb girdle muscular dystrophy 2A. Skelet Muscle 6:11|
|Reyhan, Meral L; Wang, Zhe; Kim, Hyun J et al. (2016) Effect of free-breathing on left ventricular rotational mechanics in healthy subjects and patients with duchenne muscular dystrophy. Magn Reson Med :|
|Capote, Joana; Kramerova, Irina; Martinez, Leonel et al. (2016) Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype. J Cell Biol 213:275-88|
|Srinivasan, Subashini; Kroeker, Randall M; Gabriel, Simon et al. (2016) Free-breathing variable flip angle balanced SSFP cardiac cine imaging with reduced SAR at 3T. Magn Reson Med 76:1210-6|
|Brown, Robert; Lee, Hane; Eskin, Ascia et al. (2016) Leveraging ancestry to improve causal variant identification in exome sequencing for monogenic disorders. Eur J Hum Genet 24:113-9|
|Young, Courtney S; Hicks, Michael R; Ermolova, Natalia V et al. (2016) A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell 18:533-40|
|Kramerova, Irina; Ermolova, Natalia; Eskin, Ascia et al. (2016) Failure to up-regulate transcription of genes necessary for muscle adaptation underlies limb girdle muscular dystrophy 2A (calpainopathy). Hum Mol Genet 25:2194-2207|
|Gibbs, Elizabeth M; Marshall, Jamie L; Ma, Eva et al. (2016) High levels of sarcospan are well tolerated and act as a sarcolemmal stabilizer to address skeletal muscle and pulmonary dysfunction in DMD. Hum Mol Genet :|
|Mokhonova, Ekaterina I; Avliyakulov, Nuraly K; Kramerova, Irina et al. (2015) The E3 ubiquitin ligase TRIM32 regulates myoblast proliferation by controlling turnover of NDRG2. Hum Mol Genet 24:2873-83|
|Arboleda, Valerie A; Lee, Hane; Dorrani, Naghmeh et al. (2015) De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay. Am J Hum Genet 96:498-506|
Showing the most recent 10 out of 48 publications